Infections caused by extended-spectrum beta-lactamases producing Enterobacteriaceae: Clinical and economic impact in patients hospitalized in 2 teaching hospitals in Dakar, Senegal

Antimicrobial Resistance and Infection Control

Volumn 5, Issue 1, 2016, Pages

  Ndir, Awa ^a,b,e   Diop, Amadou ^c   Ka, Roughyatou ^d   Faye, Pape Makhtar ^c   Dia Badiane, Ndeye Mery ^d   Ndoye, Babacar ^e   Astagneau, Pascal ^f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT PASTEUR DE DAKAR   (Senegal)

^c Hôpital Pédiatrique Albert Royer   (Senegal)

^d Centre Hospitalier Universitaire Dakar   (Senegal)

^e Infection Control Africa Network   (South Africa)

^f University Sorbonne Paris Cité and OST Hcéres   (France)

Author keywords

Africa; Antibiotic resistance; Cost of illness; Economic; Enterobacteriaceae; ESBL; Impact; Multistate model

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ARTIFICIAL VENTILATION; CASE FATALITY RATE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; COST OF ILLNESS; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HUMAN; INCIDENCE; INFANT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEWBORN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENEGAL; TEACHING HOSPITAL;

EID: 85007358962     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/s13756-016-0114-7     Document Type: Article

References (37)

1. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-71.
2. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum beta-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257-62.
3. Paterson DL, Bonomo R. A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-86.
4. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Inf Dis. 2001;32:1162-71.
5. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, et al. Risk factors for Increasing multidrug resistance among Extended-Spectrum β-Lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis. 2005;40:1317-24.
6. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum beta-lactamase producing Enterobacteriaceae. Antimicrob Agents Chemother. 2005;49:2137-9.
7. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;10:1791-8.
8. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6:653-6.
9. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Inf Dis. 2009;9:228-36.
10. Storberg V. ESBL producing Enterobacteriaceae in Africa-a non systematic literature review of research published 2008-2012. Infect Ecol Epidemiol. 2014;4:2032.
11. Tansarli GS, Poulikakis P, Kapaskelis A, Falagas ME. Proportion of extendedspectrum bet-lactamases (ESBL)-producing isolates among Enterobacteriaceae in Africa: evaluation of the evidence-systematic review. J Antimicrob Chemother. 2014;69:1177-84.
12. World Health Organization. Handbook Integrated Management of Childhood Illness. 2005. Available from:http://www.who.int/maternal_child_adolescent/documents/9241546441/en/.If applicable, please provide the access dates of references 12, 13, 23, 33 and 37.Not applicable
13. Société Française de Microbiologie. European Society of Clinicial Microbiology and Infectious Diseases. Comité de l'antibiothérapie de la Société Française de Microbiologie. Recommendations. 2015. Available from: http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM_EUCAST_V1_2015.pdf.
14. Stewardson A, Fankhauser C, De Angelis G, Rohner P, Safran E, Schrenzel J, et al. Burden of bloodstream infection caused by extended-spectrum betalactamase-producing Enterobacteriaceae determined using multistate modeling at a Swiss University Hospital and a nationwide predictive model. Infect Control Hosp Epidemiol. 2013;34:133-43.
15. De Angelis G, Allignol A, Murthy A, Wolkewitz M, Beyersmann J, Safran E, et al. Multistate modelling to estimate the excess length of stay associated with meticillin-resistant Staphylococcus aureus colonisation and infection in surgical patients. J Hosp Infect. 2011;78:86-91.
16. Aalen O, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat. 1978;5:141-50.
17. Datta S, Satten GA. Validity of the Aalen-Johansen estimators of stage occupation probabilities and Nelson-Aalen estimators of integrated transition hazards for non-Markov models. Statist Probabil Lett. 2001;55:403-11.
18. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals and other measures of statistical accuracy. Statist Sc. 1986;1:54-77.
19. Beyersmann J. A random time interval approach for analyzing the impact of a possible intermediate event on a terminal event. Biometr J. 2007;49:742-9.
20. Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli influence of extended-spectrum beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54:4085-91.
21. Lee SY, Kotapati S, Kuti JL, et al. Impact of Extented-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006;27:1226-32.
22. Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Micro Inf. 2014;20:973-9.
23. Worldbank data indicators. Available from:http://data.worldbank.org/indicator.
24. Burke RM, Rebolledo PA, Embrey SR, Wagner LD, Cowden CL, Kelly FM, et al. The burden of pediatric diarrhea: a cross-sectional study of incurred costs and perceptions of cost among Bolivian families. BMC Public Health. 2013;13:70
25. Bhojani U, Thriveni BS, Devadasan R, Munegowda CM, Devadasan N, Kolsteren P, et al. Out-of-pocket healthcare payments on chronic conditions impoverish urban poor in Bangalore, India. BMC Public Health. 2012;12:990.
26. Kruk ME, Goldmann E, Galea S. Borrowing and selling to pay for health care in a low and middle-income country. Health Aff. 2009;28:1056-66.
27. De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Micro Inf. 2010;16:1729-35.
28. Barnett AG, Beyersmann J, Allignol A, Rosenthal VD, Graves N, Wolkewitz M. The time-dependent bias and its effect on extra length of stay due to nosocomial infection. Value Health. 2011;14:381-6.
29. Beyersmann J, Kneib T, Schumacher M, Gastmeier P. Nosocomial infection, length of stay, and time-dependent bias. Infect Control Hosp Epidemiol. 2009;30:273-6.
30. Schumacher M. An easy mathematical proof showed that time-depended bias is inevitably leads to biased effect estimation. J Clin Epidemiol. 2008;61:1216-21.
31. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae: importantce of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1984-94.
32. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase producing Enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005;165:1375-80.
33. World Health Organization. Hand hygiene self-assessment framework. http://www.who.int/gpsc/country_work/hhsa_framework_October_2010.pdf.
34. Hilburn J, Hammond BS, Fendler EJ, Groziak PA. Use of alcohol hand sanitizer as an infection control strategy in an acute care facility. Am J Infect Control. 2003;31:109-16.
35. Cimiotti JP, Stone PW, Larson EL. A cost comparison of hand hygiene regimes. Nurs Econ. 2004;22:196-9. 204,175.
36. Jarlier V, Trystram D, Brun-Buisson C, et al. Curbing methicillin resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med. 2010;170:552-9.
37. World Health Organization. African Patient Safety Program. Available from: http://who.int/patientsafety/implementation/apps/events/ABHR-workshopreport.pdf.